Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.54 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.50 |
| ▸ | DPP4 | P27487 | 5/20 | 0.49 |
| ▸ | REN | P00797 | 2/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL873458 | 1.00 | PARP1 (0.54) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL4309187 | 1.00 | PARP1 (0.54) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL23540172 | 0.94 | NR1H2 (0.50) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL874393 | 0.93 | NR1H2 (0.52) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL877750 | 0.93 | NR1H2 (0.52) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL877749 | 0.93 | NR1H2 (0.52) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL8238773 | 0.90 | PARP1 (0.54) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL15205855 | 0.89 | PARP1 (0.56) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL2083157 | 0.89 | NR1H2 (0.51) | PARP1NR1H2NR1H3CA1CA2 | |
| SCHEMBL873617 | 0.89 | NR1H2 (0.51) | PARP1NR1H2NR1H3CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174867-A1 | CORROSION INHIBITING COATING COMPOSITIONS | PRC-DESOTO INTERNATIONAL, INC. (US) | 2024-05-30 | — | — | US | claimed |
| CN-117321150-A | Corrosion inhibiting coating composition | PRC-迪索托国际公司 | 2023-12-29 | — | — | CN | claimed |
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| CN-104046246-A | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PROD & CHEM | 2014-09-17 | — | — | CN | claimed |
| WO-2026099594-A1 | THERAPEUTIC BIFUNCTIONAL AGENTS | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2026-05-15 | — | — | WO | disclosed |
| US-12577412-B2 | Corrosion inhibiting coating compositions | PRC-DESOTO INTERNATIONAL, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | KINETA INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12234225-B2 | IL-17 ligands and uses thereof | DICE ALPHA, INC. (US) | 2025-02-25 | — | — | US | disclosed |
| EP-4444316-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | Kineta, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| CN-115745960-B | Compound containing quinolinone amide, preparation method, pharmaceutical composition and application thereof | 中国科学院上海药物研究所 | 2024-08-30 | — | — | CN | disclosed |
| US-20240174867-A1 | CORROSION INHIBITING COATING COMPOSITIONS | PRC-DESOTO INTERNATIONAL, INC. (US) | 2024-05-30 | — | — | US | disclosed |
| US-5856326-A | ANTITUMOR, ANTICANCER AGENTS | MERCK & CO., INC. (US) | 1999-01-05 | — | — | US | disclosed |
| CN-1195340-A | Inhibitors of farnesyl-protein transferase | MERCK & CO INC (US) | 1998-10-07 | — | — | CN | disclosed |
| US-5736539-A | ANITCARCINOGENIC AGENTS | MERCK & CO., INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0820445-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | Merck & Co., Inc. (US) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996030343-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1996-10-03 | — | — | WO | disclosed |
| EP-0703905-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO. INC. (US) | 1996-04-03 | — | — | EP | disclosed |
| WO-1995000497-A1 | INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE | MERCK & CO., INC. (US) | 1995-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250353852-A1 | COMPOUNDS AND COMPOSITIONS THAT INHIBIT PIKFYVE | PIKFYVE, TARDBP, TDP1 | PARP1 1110/4885NR1H2 4364/4885NR1H3 4363/4885 |
| US-12234225-B2 | IL-17 ligands and uses thereof | IL17A, IL2, IL15 | PARP1 3832/4885NR1H2 441/4885NR1H3 517/4885 |
| US-12577412-B2 | Corrosion inhibiting coating compositions | MGMT, MBD2, MECP2 | PARP1 1314/4885NR1H2 4869/4885NR1H3 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.